Mutations in BRAFoccur in 2-4% of lung adenocarcinoma (LUAD) patients. Combination dabrafenib/trametinib or single-agent vemurafenib is approved only for patients with cancers driven by the V600E BRAFmutation. Targeted therapy is not currently available for patients harboring non-V600 BRAFmutations.